Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Ruppert

Showing results (121-130 of 188) with videos related to

Pageof 19
Sort By:
Blood|March 8, 2007
Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B studySusan P Whitman, Amy S Ruppert, Guido Marcucci, et al.
Leukemia & Lymphoma|September 24, 2019
Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 studyBhavana Bhatnagar, Qiuhong Zhao, Alice S Mims, et al.
Blood|October 18, 2007
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplicationsSusan P Whitman, Amy S Ruppert, Michael D Radmacher, et al.
Blood|August 17, 2018
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemiaKerry A Rogers, Ying Huang, Amy S Ruppert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2004
Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461Guido Marcucci, Krzysztof Mrózek, Amy S Ruppert, et al.
Future Oncology (London, England)|November 15, 2022
BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphomaToby A Eyre, Nirav N Shah, Martin Dreyling, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 5, 2017
Serum miR-29a Is Upregulated in Acute Graft-versus-Host Disease and Activates Dendritic Cells through TLR BindingParvathi Ranganathan, Apollinaire Ngankeu, Nina C Zitzer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461John C Byrd, Amy S Ruppert, Krzysztof Mrózek, et al.
Cancer Medicine|February 17, 2023
Is local review of positron emission tomography scans sufficient in diffuse large B-cell lymphoma clinical trials? A CALGB 50303 analysisPallawi Torka, Levi D Pederson, Michael V Knopp, et al.
Ejhaem|October 17, 2024
Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapyNicole Lamanna, Constantine S Tam, Jennifer A Woyach, et al.
Pageof 19

Showing results (121-130 of 188) with videos related to

Sort By:
Pageof 19
Blood|March 8, 2007
Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B studySusan P Whitman, Amy S Ruppert, Guido Marcucci, et al.
Leukemia & Lymphoma|September 24, 2019
Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 studyBhavana Bhatnagar, Qiuhong Zhao, Alice S Mims, et al.
Blood|October 18, 2007
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplicationsSusan P Whitman, Amy S Ruppert, Michael D Radmacher, et al.
Blood|August 17, 2018
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemiaKerry A Rogers, Ying Huang, Amy S Ruppert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2004
Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461Guido Marcucci, Krzysztof Mrózek, Amy S Ruppert, et al.
Future Oncology (London, England)|November 15, 2022
BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphomaToby A Eyre, Nirav N Shah, Martin Dreyling, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 5, 2017
Serum miR-29a Is Upregulated in Acute Graft-versus-Host Disease and Activates Dendritic Cells through TLR BindingParvathi Ranganathan, Apollinaire Ngankeu, Nina C Zitzer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461John C Byrd, Amy S Ruppert, Krzysztof Mrózek, et al.
Cancer Medicine|February 17, 2023
Is local review of positron emission tomography scans sufficient in diffuse large B-cell lymphoma clinical trials? A CALGB 50303 analysisPallawi Torka, Levi D Pederson, Michael V Knopp, et al.
Ejhaem|October 17, 2024
Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapyNicole Lamanna, Constantine S Tam, Jennifer A Woyach, et al.
Pageof 19